Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ron Dagan

Showing results (331-340 of 367) with videos related to

Pageof 37
Sort By:
Vaccine|September 11, 2021
A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)Heather L Platt, Jose F Cardona, Miwa Haranaka, et al.
Pediatrics|June 13, 2023
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 StudyNatalie Banniettis, Michael Horn, Manish Sadarangani, et al.
Journal of the Pediatric Infectious Diseases Society|January 14, 2024
Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV SeasonRon Dagan, Laura L Hammitt, Beatriz Seoane Nuñez, et al.
The Lancet. Infectious Diseases|February 27, 2010
Otitis media and its consequences: beyond the earacheAnne Vergison, Ron Dagan, Adriano Arguedas, et al.
Human Vaccines & Immunotherapeutics|March 3, 2023
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factorsLaura L Hammitt, Dean Quinn, Ewa Janczewska, et al.
Vaccine|April 27, 2023
A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, et al.
Plos One|April 12, 2013
NADH oxidase functions as an adhesin in Streptococcus pneumoniae and elicits a protective immune response in miceLena Muchnik, Asad Adawi, Ariel Ohayon, et al.
Human Vaccines & Immunotherapeutics|May 3, 2016
Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)Susanna Esposito, Paolo Bonanni, Stefania Maggi, et al.
International Journal of Molecular Medicine|March 4, 2016
Streptococcus pneumoniae fructose-1,6-bisphosphate aldolase, a protein vaccine candidate, elicits Th1/Th2/Th17-type cytokine responses in miceShirin Elhaik Goldman, Shahar Dotan, Amir Talias, et al.
Vaccine|January 21, 2025
Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398]Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, et al.
Pageof 37

Showing results (331-340 of 367) with videos related to

Sort By:
Pageof 37
Vaccine|September 11, 2021
A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)Heather L Platt, Jose F Cardona, Miwa Haranaka, et al.
Pediatrics|June 13, 2023
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 StudyNatalie Banniettis, Michael Horn, Manish Sadarangani, et al.
Journal of the Pediatric Infectious Diseases Society|January 14, 2024
Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV SeasonRon Dagan, Laura L Hammitt, Beatriz Seoane Nuñez, et al.
The Lancet. Infectious Diseases|February 27, 2010
Otitis media and its consequences: beyond the earacheAnne Vergison, Ron Dagan, Adriano Arguedas, et al.
Human Vaccines & Immunotherapeutics|March 3, 2023
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factorsLaura L Hammitt, Dean Quinn, Ewa Janczewska, et al.
Vaccine|April 27, 2023
A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, et al.
Plos One|April 12, 2013
NADH oxidase functions as an adhesin in Streptococcus pneumoniae and elicits a protective immune response in miceLena Muchnik, Asad Adawi, Ariel Ohayon, et al.
Human Vaccines & Immunotherapeutics|May 3, 2016
Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)Susanna Esposito, Paolo Bonanni, Stefania Maggi, et al.
International Journal of Molecular Medicine|March 4, 2016
Streptococcus pneumoniae fructose-1,6-bisphosphate aldolase, a protein vaccine candidate, elicits Th1/Th2/Th17-type cytokine responses in miceShirin Elhaik Goldman, Shahar Dotan, Amir Talias, et al.
Vaccine|January 21, 2025
Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398]Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, et al.
Pageof 37